Rectal Cancer
Conditions
Brief summary
This is an open-label, multi-center, single-arm clinical study. All patients received 4-6 cycles total neoadjuvant therapy plus concurrent tislelizumab immunotherapy, then underwent clinical response assessment. Patients who achieved CR (cCR+ pCR confirmed by local resection of ncCR) continue tislelizumab combined with CAPOX for another 4 cycles and tislelizumab for 9 cycles, then Watch and Wait. Patients who did not achieved CR underwent total mesorectal excision (TME).
Interventions
DRUGTislelizumab
200 mg IV on Day 1 of each 21-day cycle.
DRUGCapecitabine
Capecitabine 1000 mg/m2 orally twice daily (bid) on Day 1 to 14 of each 21-day cycle in CAPOX regimen
DRUGOxaliplatin
130 mg/m2 IV on Day 1 of each 21-day cycle in CAPOX regimen
Sponsors
Fudan University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Able to provide written informed consent, understand and comply with the requirements and evaluation schedule 2. ≥18, ≤75 years old 3. Histologically confirmed rectal adenocarcinoma 4. immunohistochemistry confirmed pMMR (positive for MLH1, MSH2, MSH6 and PMS2), or PCR /NGS confirmed MSI-L or MSS 5. The tumor is within 3 cm of the dentate line. through colonoscopy, digital anal examination or MRI 6. clinical stage cT1-3 N 0-1M0 (the 8th UICC/AJCC; T and N is evaluated by MRI) 7. Resectable primary tumor assessed by the Investigator 8. Have not received any anti-tumor treatment for rectal cancer 9. ECOG PS ≤ 1 10. Adequate organ function 11. Female subjects with the ability to become pregnant must have a serum pregnancy test with a negative result within 72 hours before the first dose, and be willing to use highly effective contraceptive methods during the trial and 120 days after the last dose. Male subjects whose partners are women of childbearing potential should be surgically sterilized or agree to use a highly effective method of contraception during the trial and for 120 days after the last dose.
Exclusion criteria
1. Histologically confirmed poorly differentiated/undifferentiated adenocarcinoma, mucinous adenocarcinoma and signet ring cell carcinoma 2. Have received any treatments for rectal cancer, or evidence of distant metastasis 3. Presence of following high risk factors assessed by MRI: MRF +, EMVI+, cN2, Positive lateral lymph nodes, T3d 4. Presence or in high risk of obstruction, perforation or bleeding; 5. Not suitable for long-course radiotherapy 6. Cannot tolerate surgery 7. ≥2 colorectal cancer lesions at the same time 8. Contraindications for MRI examination 9. Other malignant tumors in the past or at the same time 10. Have an active autoimmune disease requiring systemic therapy within the past 2 years 11. HIV infection 12. Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers (HBV DNA \> 500 IU/mL) or active HCV carriers with detectable HCV RNA; 13. Hypersensitivity to any ingredient of tislelizumab, capecitabine, and oxaliplatin or to any component of the container 14. Other conditions judged by the researcher that do not meet the enrollment requirements
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete Response rate (CR rate) | From first dose up to 12 months, approximately | defined as the proportion of participants with clinical complete response(cCR) or near clinical complete response (ncCR) who achieved local resection confirmed pCR determined by the investigators after 4-6 cycles total neoadjuvant therapy plus concurrent tislelizumab immunotherapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 1/2/3 year organ-preservation rate | From first dose of radiotherapy up to 36 months, approximately | defined as the proportion of participants who survived and did not underwent TME in 1/2/3 year (in the CR set and full analysis set respectively) |
| 1/2/3 year EFS rate | From first dose of radiotherapy up to 36 months, approximately | defined as the proportion of participants who did not develop local recurrence, distant metastasis, new invasive primary lesions of colorectal cancer, or death in 1/2/3 year (in the CR set, non-CR set and full analysis set respectively) |
| 1/2/3 year OS rate | From first dose of radiotherapy up to 36 months, approximately | defined as the proportion of participants who survived in 1/2/3 year (in the full analysis set) |
| Percentage of Participants With Adverse Events | From first dose of radiotherapy up to 36 months, approximately | Percentage of Participants With adverse events (AEs) , immune-related adverse events(irAE) and serious adverse events (SAEs) per the National Cancer Institute CommonTerminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 |
Countries
China
Contacts
CONTACTJianmin Xu, MD
CONTACTWenju Chang, MD
Outcome results
None listed